Michel Sylvain

Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders

Chemically Modified Platforms for Better RNA Therapeutics

Dystrophin Expression in Muscles of Duchenne Muscular Dystrophy Patients After High-Density Injections of Normal Myogenic Cells

First test of a “high-density injection” protocol for myogenic cell transplantation throughout large volumes of muscles in a Duchenne muscular dystrophy patient: eighteen months follow-up